Blog Posts

Fady Geara: Phase II Study of Upfront Immunotherapy with Radiation and TNT in MS-S Rectal Cancer

Fady Geara/LinkedIn

Apr 26, 2025, 12:32

Fady Geara: Phase II Study of Upfront Immunotherapy with Radiation and TNT in MS-S Rectal Cancer

Fady Geara, Professor and Chairman at Cleveland Clinic Abu Dhabi, posted on LinkedIn:

“Our multi institutional phase II pilot study adding upfront immunotherapy to short course radiation and TNT in MS-S rectal ca recently published. Promising results; pCR 37.5%: Major Path response 67.5%. Local disease control 97.5%.

Immunotherapy score highly predictive. Excellent work by the AUB GI oncology team and all investigators inside and outside AUB. Congratulations on this highly contributing study.”

“Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study.”

Authors: Ali Shamseddine, Rim Turfa, Laudy Chehade, Youssef H. Zeidan, Ziad El Husseini, Malek Kreidieh, Youssef Bouferraa, Charbel Elias, Joseph Kattan, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Yasser Shaib, Assaad Soweid, Kholoud Alqasem, Rula Amarin, Tala Al Awabdeh, Samer Deeba, Samer Doughan, Issa Mohamad, Fady Geara

Ali Shamseddine Assaad Soweid cancer Charbel Elias Deborah Mukherji Fady Geara GI cancer Ibrahim Khalifeh immunotherapy Issa Mohamad Joseph Kattan Kholoud Alqasem Laudy Chehade Malek Kreidieh OncoDaily Oncology rectal cancer Rim Turfa Rula Amarin Sally Temraz Samer Deeba Samer Doughan Tala Al Awabdeh Yasser Shaib Youssef Bouferraa Youssef H. Zeidan Ziad El Husseini

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth